Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Income towards Parent Company (2018 - 2025)

Addex Therapeutics' Income towards Parent Company history spans 8 years, with the latest figure at -$6.0 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 46.06% to -$6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.0 million, a 46.06% increase, with the full-year FY2025 number at -$5.6 million, down 314.85% from a year prior.
  • Income towards Parent Company came in at -$6.0 million for Q4 2025, down from $142225.5 in the prior quarter.
  • The five-year high for Income towards Parent Company was $15.9 million in Q2 2024, with the low at -$23.2 million in Q4 2021.
  • Historically, Income towards Parent Company has averaged -$3.9 million across 5 years, with a median of -$2.9 million in 2021.
  • Biggest five-year swings in Income towards Parent Company: tumbled 796.04% in 2023 and later surged 761.78% in 2024.
  • Year by year, Income towards Parent Company stood at -$23.2 million in 2021, then soared by 106.43% to $1.5 million in 2022, then crashed by 796.04% to -$10.4 million in 2023, then decreased by 6.67% to -$11.1 million in 2024, then soared by 46.06% to -$6.0 million in 2025.
  • Business Quant data shows Income towards Parent Company for ADXN at -$6.0 million in Q4 2025, $142225.5 in Q2 2025, and -$1.6 million in Q1 2025.